Literature DB >> 22262778

Unique features of primary myelofibrosis in Chinese.

Zefeng Xu1, Robert Peter Gale, Yue Zhang, Tiejun Qin, Huishu Chen, Peihong Zhang, Tianjiao Zhang, Liu Liu, Shiqiang Qu, Zhijian Xiao.   

Abstract

Clinical and laboratory features of 642 consecutive Chinese subjects with primary myelofibrosis (PMF) were analyzed and compared with those of 1054 predominately white subjects with PMF. Chinese subjects were significantly younger, fewer had constitutional symptoms, and fewer had a palpable spleen or liver. Anemia, in contrast, was significantly more common in Chinese as was an increased white blood cell count and low platelet count. The reason for these differences is unclear, but it does not seem to be correlated with delayed diagnosis. A small but significantly increased proportion of Chinese had the JAK2(V617F) mutation but no difference in the frequency of haplotypes associated with PMF in whites. Survival of Chinese with PMF was also significantly longer than that of whites with PMF. We found commonly used staging systems for PMF such as the International Prognostic Scoring System and the Dynamic International Prognostic Scoring System were suboptimal predictors of survival in Chinese with PMF, and we developed a revised prognostic score that should help in comparison of data between studies of PMF in different populations and planning of clinical trials.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22262778     DOI: 10.1182/blood-2011-11-389866

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?

Authors:  G Barosi; M-J Zhang; R Peter Gale
Journal:  Leukemia       Date:  2014-07-16       Impact factor: 11.528

2.  Ruxolitinib and survival improvement in patients with myelofibrosis.

Authors:  F Passamonti; A M Vannucchi; F Cervantes; C Harrison; E Morra; H Kantarjian; S Verstovsek
Journal:  Leukemia       Date:  2014-09-24       Impact factor: 11.528

3.  Mortality outcomes and survival patterns of patients with myeloproliferative neoplasms in Malaysia.

Authors:  Yee Yee Yap; Jameela Sathar; Kian Boon Law
Journal:  Cancer Causes Control       Date:  2021-11-30       Impact factor: 2.506

4.  Mutational spectrum and prognosis in Chinese patients with prefibrotic primary myelofibrosis.

Authors:  Chi-Keung Cheng; Jennifer W Y Lai; Yuk-Lin Yung; Hoi-Yun Chan; Raymond S M Wong; Natalie P H Chan; Joyce S Cheung; Xi Luo; Herbert-Augustus Pitts; Margaret H L Ng
Journal:  EJHaem       Date:  2021-12-30

5.  Calreticulin mutations in Chinese with primary myelofibrosis.

Authors:  Bing Li; Junqing Xu; Jingya Wang; Robert Peter Gale; Zefeng Xu; Yajuan Cui; Lin Yang; Ruixian Xing; Xiaofei Ai; Tiejun Qin; Yue Zhang; Peihong Zhang; Zhijian Xiao
Journal:  Haematologica       Date:  2014-07-04       Impact factor: 9.941

6.  Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.

Authors:  Samer A Srour; Susan S Devesa; Lindsay M Morton; David P Check; Rochelle E Curtis; Martha S Linet; Graça M Dores
Journal:  Br J Haematol       Date:  2016-04-07       Impact factor: 6.998

7.  Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Authors:  Holly L Geyer; Heidi Kosiorek; Amylou C Dueck; Robyn Scherber; Stefanie Slot; Sonja Zweegman; Peter Aw Te Boekhorst; Zhenya Senyak; Harry C Schouten; Federico Sackmann; Ana Kerguelen Fuentes; Dolores Hernández-Maraver; Heike L Pahl; Martin Griesshammer; Frank Stegelmann; Konstanze Döhner; Thomas Lehmann; Karin Bonatz; Andreas Reiter; Francoise Boyer; Gabriel Etienne; Jean-Christophe Ianotto; Dana Ranta; Lydia Roy; Jean-Yves Cahn; Claire N Harrison; Deepti Radia; Pablo Muxi; Norman Maldonado; Carlos Besses; Francisco Cervantes; Peter L Johansson; Tiziano Barbui; Giovanni Barosi; Alessandro M Vannucchi; Chiara Paoli; Francesco Passamonti; Bjorn Andreasson; Maria L Ferrari; Alessandro Rambaldi; Jan Samuelsson; Keith Cannon; Gunnar Birgegard; Zhijian Xiao; Zefeng Xu; Yue Zhang; Xiujuan Sun; Junqing Xu; Jean-Jacques Kiladjian; Peihong Zhang; Robert Peter Gale; Ruben A Mesa
Journal:  Haematologica       Date:  2016-08-18       Impact factor: 9.941

8.  The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry.

Authors:  Chris Varghese; Tracey Immanuel; Anna Ruskova; Edward Theakston; Maggie L Kalev-Zylinska
Journal:  Curr Oncol       Date:  2021-04-18       Impact factor: 3.677

9.  Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN).

Authors:  Gregory L Price; Keith L Davis; Sudeep Karve; Gerhardt Pohl; Richard A Walgren
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

10.  Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.

Authors:  Nur Soyer; İbrahim C Haznedaroğlu; Melda Cömert; Demet Çekdemir; Mehmet Yılmaz; Ali Ünal; Gülsüm Çağlıyan; Oktay Bilgir; Osman İlhan; Füsun Özdemirkıran; Emin Kaya; Fahri Şahin; Filiz Vural; Güray Saydam
Journal:  Turk J Haematol       Date:  2016-04-18       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.